Internet Archive Scholar

Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort

Antonella d'Arminio Monforte, Patrizia Lorenzini, Alessandro Cozzi-Lepri, Cristina Mussini, Antonella Castagna, Franco Baldelli, Massimo Puoti, Francesca Vichi, Adelaide Maddaloni, Sergio Lo Caputo, Nicola Gianotti, Andrea Antinori
2018 HIV Clinical Trials  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (1.3 MB)
https://web.archive.org/web/20190501135909/http://discovery.ucl.ac.uk/10045414/1/Cozzi-Lepri_Paper_HCT_darminio.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL. The file type is application/pdf.

4 Background: We aimed to mimic the ACTG 5257 trial, comparing raltegravir (RAL), 5 ritonavir-boosted atazavavir (ATV/r) and ritonavir-boosted darunavir (DRV/r) in the 6 observational setting. 24 Conclusions: In our observational study, we confirmed higher risk of treatment failure 25 and lower tolerability of ATV/r-based regimens as compared to those including DRV/r or 26 RAL. 27
doi:10.1080/15284336.2018.1440691 pmid:29493419 fatcat:7u7bfkmm5vgd3nlwmdkw2vvkpq
Citation

Antonella d'Arminio Monforte, Patrizia Lorenzini, Alessandro Cozzi-Lepri, Cristina Mussini, Antonella Castagna, Franco Baldelli, Massimo Puoti, Francesca Vichi, Adelaide Maddaloni, Sergio Lo Caputo, Nicola Gianotti, Andrea Antinori. "Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort." HIV Clinical Trials 19.2 (2018) 52-60